31 March 2014
: Case report
A case report of hydralazine-induced skin reaction: Probable toxic epidermal necrolysis (TEN)
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Ahmed MahfouzE, Ahmed Naguib MahmoudD, Patel Ahmad AshfaqB, Khalid Hamed Al SiyabiEDOI: 10.12659/AJCR.890038
Am J Case Rep 2014; 15:135-138
Abstract
Background: Skin reactions are common adverse drug reactions and may include angioedema, erythroderma, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN). TEN is a rare but serious reaction characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes.
Case Report: An elderly woman presented with generalized weakness and nausea, associated with a hypertensive crisis. Following the initiation of hydralazine, well-demarcated erythematous maculopapular rashes appeared on her right forearm and left leg, which transformed into a bullous rash. Subsequently, a similar patch appeared on her left forearm, with a similar progression and associated with generalized edema of the extremities.
A clinical diagnosis of drug-induced toxic epidermal necrolysis was made and hydralazine was discontinued. Following this, the skin lesions improved, with complete subsequent resolution. Skin biopsy was not performed due to the rapid resolution of the lesions. A negative screen for autoantibodies ruled out systemic lupus erythematosus, scleroderma, and other undifferentiated connective tissue disorders.
After re-administration of hydralazine, the same lesions appeared again, which again resolved after its discontinuation, thus confirming our initial clinical suspicion.
Treatment is immediate discontinuation of the offending drug and supportive care.
Conclusions: Clinical awareness with close monitoring is important for the identification of a rare adverse drug reaction, which can be fatal if not diagnosed and treated promptly.
Keywords: Hydralazine - adverse effects, Stevens-Johnson Syndrome
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946514
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946456
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945602
Most Viewed Current Articles
21 Jun 2024 : Case report
90,010
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,284
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,908
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,715
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030